Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a

Blood

Volumn 106, Issue 4, 2005, Pages 1355-1361

  Zhang, Bin ^b   Groffen, John ^b   Heisterkamp, Nora ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; ATP11A PROTEIN; BCR ABL PROTEIN; CYTOTOXIC AGENT; GGTI 298; IMATINIB; LONAFARNIB; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; DIAGNOSTIC VALUE; DRUG MECHANISM; DRUG SENSITIVITY; GENE OVEREXPRESSION; GENE SEQUENCE; LYMPHATIC LEUKEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 23744461504     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-09-3655     Document Type: Article

References (48)

1. Heisterkamp N, Groffen J. BCR/ABL gene structure and BCR function. In: Carella AM, Daley GQ, Eaves CM, Goldman JM, Hehlman R, eds. Chronic Myeloid Leukemia: Biology and Treatment. Oxford, United Kingdom: Martin Dunitz Ltd; 2001:3-17.
2. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
3. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998-1006.
4. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-2366.
5. Faderl S, Garcia-Manero G, Thomas DA, Kantarjian HM. Philadelphia chromosome-positive acute lymphoblastic leukemia: current concepts and future perspectives. Rev Clin Exp Hematol. 2002;6:142-160.
6. Hoelzer D, Gokbuget N, Ottmann OG. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Semin Hematol. 2002;39:32-37.
7. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL. Leukemia. 2003;17:691-699.
8. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003;40:79-86.
9. Holtz MS, Bhatia R. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. Leuk Lymphoma. 2004;45:237-245.
10. Tipping AJ, Baluch S, Barnes DJ, et al. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia. 2004;18:1352-1356.
11. Mishra S, Zhang B, Groffen J, Heisterkamp N. Treatment of advanced P190 Bcr/Abl positive leukemia with a farnesyltransferase inhibitor. Leukemia. 2004;18:23-28.
12. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
13. Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive ALL in P190 transgenic mice with the farnesyltransferase inhibitor SCH66336. Blood. 2001;97:399-1403.
14. Brodsky AL. Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line. Blood. 2003;101:2070-2071.
15. Daley GQ. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Semin Hematol. 2003;40:11-14.
16. Hoover RR, Mahon FX, MeIo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068-1071.
17. Nakajima A, Tauchi T, Sumi M, Bishop WR, Ohyashiki K. Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther. 2003;2:219-224.
18. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004;11:35-43.
19. Weisbeg E, Griffin JD. Resistance to Imatinib (Glivec): update on clinical mechanisms. Drug Resist Update. 2003;6:231-238.
20. Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004;45:2187-2195.
21. Karp JE, Lancet JE. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies. Ann Hematol. 2004;83(suppl 1):S87-S88.
22. Russo P, Loprevite M, Cesario A, Ardizzoni A. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic. Curr Med Chem Anti-Canc Agents. 2004;4:123-138.
23. Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs. 2003;12:1428-1435.
24. Voncken J-W, Griffiths S, Greaves MF, Pattengale PK, Heisterkamp N, Groffen J. Restricted oncogenicity of BCR/ABL P190 in transgenic mice. Cancer Res. 1992;52:4534-4539.
25. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukemia in BCR/ABL transgenic mice. Nature. 1990;344:251-254.
26. Schageman JJ, Horton CJ, Niu S, Garner HR, Pertsemlidis A. ELXR: a resource for rapid exon-directed sequence analysis. Genome Biol. 2004;5:R36.
27. Goda SK, Minton NP. A simple procedure for gel electrophoresis and Northern blotting of RNA. Nucl Acids Res. 1995;23:3357-3358.
28. Su YR, Linton MF, Fazio SJ. Rapid quantification of murine ABC mRNAs by real time reverse transcriptase-polymerase chain reaction. Lipid Res. 2002;43:2180-2187.
29. Weizmann Institute of Science. GeneCards: database of human genes, their products and their involvement in diseases. http://bioinfo.weizmann.ac.il/cards/ index.shtml. Accessed on June 10, 2005.
30. Del Villar K, Urano J, Guo L, Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. J Biol Chem. 1999;274:27010-27017.
31. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000;6:2318-2325.
32. Del Villar K, Mitsuzawa H, Yang W, Sattler I, Tamanoi F. Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. J Biol Chem. 1997;272:680-687.
33. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
34. Halleck MS, Lawler JF Jr, Blackshaw S, et al. Differential expression of putative transbilayer amphipath transporters. Physiol Genomics. 1999;1:139-150.
35. Ashar HR, James L, Gray K, et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2) -> M orG(1) pause in sensitive human tumor cell lines. Exp Cell Res. 2001;262:17-27.
36. Njoroge FG, Taveras AG, Kelly J, et al. (+)-4-[2-[4-(8-Chloro-3,10- dibromo-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]-pyridin-11(R)-yl) -1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide(SCH-66336): a very potent famesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem. 1998;41:4890-4902.
37. Roskoski R Jr. Protein prenylation: a pivotal post-translational process. Biochem Biophys Res Commun. 2003;303:1-7.
38. Morgan MA, Wegner J, Aydilek E, Ganser A, Reuter CW. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia. 2003;17:1508-1520.
39. van de Donk NW, Schotte D, Kamphuis MM, et al. Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res. 2003;9:5735-5748.
40. Ronghe M, Burke GA, Lowis SP, Estlin EJ. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. Cancer Treat Rev. 2001;27:27-37.
41. Smith V, Rowlands MG, Barrie E, Workman P, Kelland LR. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res. 2002;6:2002-2009.
42. Srivastava N. ATP binding cassette transporter A1: key roles in cellular lipid transport and atherosclerosis. Mol Cell Biochem. 2002;237:155-164.
43. Gan X, Kaplan R, Menke JG, et al. Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem. 2001;276:48702-48708.
44. Wang EJ, Johnson WW. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy. 2003;49:303-308.
45. Oude Elferink R, Groen AK. Genetic defects in hepatobiliary transport. Biochim Biophys Acta. 2002;1586:129-145.
46. National Center for Biotechnology Information. UniGene: gene-oriented clusters of transcript sequences. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? db=unigene. Accessed on June 10, 2005.
47. Cortes J. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma. 2003;4:S30-S35.
48. Smalley KS, Eisen TG. Farnesyltransferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer. 2003;105:165-175.